Valneva: EMA accepts marketing authorisation application for
(CercleFinance.com) - Valneva confirms that the European Medicines Agency (EMA) has accepted the submission of the marketing authorisation application (MAA) for its candidate inactivated whole-virus vaccine against Covid-19, VLA2001.
VLA2001 thus enters the formal evaluation process by the Committee for Medicinal Products for Human Use (CHMP). If the CHMP accepts the conditional marketing authorisation application, Valneva could obtain a positive opinion from the CHMP in June 2022.
If the CHMP gives a positive opinion, the European Commission will review the recommendation and make a final decision on the MA, which would be valid in all EU Member States as well as Iceland, Liechtenstein and Norway.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
VLA2001 thus enters the formal evaluation process by the Committee for Medicinal Products for Human Use (CHMP). If the CHMP accepts the conditional marketing authorisation application, Valneva could obtain a positive opinion from the CHMP in June 2022.
If the CHMP gives a positive opinion, the European Commission will review the recommendation and make a final decision on the MA, which would be valid in all EU Member States as well as Iceland, Liechtenstein and Norway.
Copyright (c) 2022 CercleFinance.com. All rights reserved.